BPC June 10 update

EHA Data released; Caribou CRBU Down off Phase 1; COGT Up off Phase 2 data

Pre-Market Updates

Yesterday's BIOrdle ticker was GMTX. Gemini Therapeutics, Inc. (NASDAQ: GMTX) is a clinical stage company developing treatments for age-related macular degeneration (AMD). Gemini announced in February a corporate restructuring plan to focus on its product, GEM307, and its Investigational New Drug (IND)-enabling tasks. Shares closed yesterday up 2% at $1.54.


Caribou Biosciences (NASDAQ: CRBU) reported initial data from its Phase 1 ANTLER trial of CB-010, a CAR-T cell therapy to treat relapsed or refractory B cell non-Hodgkin lymphoma. After a single dose at the initial dose level, a 100% complete response (CR) rate was reported.

Cogent Biosciences, Inc. (NASDAQ: COGT) announced initial data from its Phase 2 APEX trial of bezuclastinib to treat advanced systemic mastocytosis (AdvSM). 100% of patients achieved ≥50% reduction in serum tryptase levels by central assessment with 89% median reduction in serum tryptase, and six of these patients achieved reduction to <20 ng/mL.

Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) announced topline data from its Phase 2 MELAS trial of CY6463 to treat Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like Episodes (MELAS). CY6463 was well tolerated with no adverse events leading to treatment discontinuation, and improvements in biomarkers associated with mitochondrial function including lactate and GDF-15 were noted.

CTI BioPharma Corp. (NASDAQ: CTIC) announced a presentation regarding pacritinib is set to be presented at the European Hematology Association (EHA) 2022 Congress. The presentation compares patient outcomes on pacritinib versus ruxolitinib to treat myelofibrosis and thrombocytopenia, noting that overall and fatal adverse events occurred at similar rates but cardiac events occurred more commonly on pacritinib.

MEI Pharma, Inc. (NASDAQ: MEIP) and Kyowa Kirin Co., Ltd. announced data from the Phase 2 TIDAL study of zandelisib to treat B-cell malignancies. Zandelisib demonstrated 70.3% objective response rate and 35.2% complete response rate, 87.5% of responses achieved in first two cycles of therapy, and 75% of complete responses in first four cycles. 9.9% of patients discontinued therapy due to a drug related adverse event.

bluebird bio, Inc. (NASDAQ: BLUE) announced that an FDA advisory committee voted in favor of approval for elivaldogene autotemcel (eli-cel) to treat early active cerebral adrenoleukodystrophy (CALD). Today, June 10, 2022, the committee will discuss the efficacy and safety of betibeglogene autotemcel (beti-cel) to treat beta-thalassemia in patients who require regular red blood cell transfusions.

Tiziana Life Sciences Ltd. (NASDAQ: TLSA) announced that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, purchased 50,000 common shares at $0.88 per share.

Pre-Market Advancers

Talaris Therapeutics Inc.
$1.01 +1.01  +100%
Akouos Inc.
$1.01 +1.01  +100%
Quoin Pharmaceuticals Ltd.
$1.01 +1.01  +100%
Brickell Biotech, Inc.
$1.01 +1.01  +100%
Akebia Therapeutics Inc.
$1.01 +1.01  +100%
Allena Pharmaceuticals Inc.
$1.01 +1.01  +100%
Provention Bio Inc.
$1.01 +1.01  +100%
Invacare Corporation
$1.01 +1.01  +100%
Ensysce Biosciences Inc.
$1.01 +1.01  +100%
Benitec Biopharma Inc.
$1.01 +1.01  +100%

Pre-Market Decliners

Candel Therapeutics Inc.
$1.01 -1.01  -100%
Clovis Oncology Inc.
$1.01 -1.01  -100%
Endo International plc
$1.01 -1.01  -100%
Tyra Biosciences Inc.
$1.01 -1.01  -100%
Cytek Biosciences Inc.
$1.01 -1.01  -100%
Belite Bio Inc
$1.01 -1.01  -100%
Mereo BioPharma Group plc
$1.01 -1.01  -100%
Cortexyme Inc.
$1.01 -1.01  -100%
Pulmatrix Inc.
$1.01 -1.01  -100%
RxSight Inc.
$1.01 -1.01  -100%